Laurion Capital Management’s Damora Therapeutics DMRA Stock Holding History

Laurion Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,543	Closed	-$63.7K	–	536
2023 Q3	$63.7K	Sell	3,543 -4,083	-54%	-$160K	﹤0.01%	460
2023 Q2	$480K	Hold	7,626	–	–	﹤0.01%	424
2023 Q1	$379K	Hold	7,626	–	–	﹤0.01%	356
2022 Q4	$219K	Hold	7,626	–	–	﹤0.01%	380
2022 Q3	$360K	Hold	7,626	–	–	﹤0.01%	415
2022 Q2	$330K	Hold	7,626	–	–	0.01%	363
2022 Q1	$419K	Sell	7,626 -168	-2%	-$9.44K	0.01%	392
2021 Q4	$590K	Hold	7,794	–	–	0.01%	401
2021 Q3	$700K	Sell	7,794 -508	-6%	-$54.3K	﹤0.01%	545
2021 Q2	$1.05M	Hold	8,302	–	–	0.01%	434
2021 Q1	$1.26M	Hold	8,302	–	–	0.01%	472
2020 Q4	$2.59M	Buy	+8,302	New	+$3.09M	0.02%	321

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Laurion Capital Management's DMRA Position: Q4 2023 in Review

Laurion Capital Management sold out of Damora Therapeutics (DMRA) in Q4 2023, closing a stake of 3,543 shares — an estimated $63.7K sold.

Laurion Capital Management first reported a position in DMRA in Q4 2020 and held it in 12 quarters. The position peaked at $2.59M in Q4 2020. 21 funds tracked by Wall St. Rank hold DMRA as of Q4 2023.

Laurion Capital Management reported no remaining Damora Therapeutics position as of Q4 2023 after selling out during the quarter.
Laurion Capital Management sold 3,543 Damora Therapeutics shares in Q4 2023, an estimated $63.7K.
Laurion Capital Management first reported a position in Damora Therapeutics in Q4 2020 and held it in 12 quarters.
Laurion Capital Management's Damora Therapeutics position peaked at $2.59M in Q4 2020.
21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.